Abivax (AAVXF) Other Non-Current Liabilities (2022 - 2026)

Abivax has reported Other Non-Current Liabilities for 5 years, with the latest figure at $26.0 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $26.0 million in Q1 2026; TTM through Mar 2026 was $26.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $41.1 million, down 66.27% from the prior year.
• Other Non-Current Liabilities was $26.0 million for Q1 2026 at Abivax, down from $41.1 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $183.7 million in Q2 2025, with the low at $26.0 million in Q1 2026.
• Average Other Non-Current Liabilities over 5 years is $101.3 million, with a median of $104.2 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities soared 165.13% in 2023, then slumped 66.27% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $50.8 million in 2022, then jumped by 165.13% to $134.7 million in 2023, then retreated by 9.56% to $121.8 million in 2024, then plunged by 66.27% to $41.1 million in 2025, then sank by 36.75% to $26.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $26.0 million (Q1 2026), $41.1 million (Q4 2025), and $86.5 million (Q3 2025), per Business Quant data.